We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Triple COVID-19 Antibody Testing Device Indicates Prior SARS-CoV-2 Infection and If Your Vaccine Worked

By LabMedica International staff writers
Posted on 19 Aug 2021
Print article
Image: Triple COVID-19 Antibody Testing Device Indicates Prior SARS-CoV-2 Infection and If Your Vaccine Worked (Photo courtesy of Mantracourt Electronics Limited)
Image: Triple COVID-19 Antibody Testing Device Indicates Prior SARS-CoV-2 Infection and If Your Vaccine Worked (Photo courtesy of Mantracourt Electronics Limited)
A new seven-minute COVID-19 antibody testing device can tell you if you have had COVID-19 and if your vaccine worked.

Mantracourt Electronics Limited (Devon, UK) helped engineer the new COVID-19 triple antibody testing device which was designed by Attomarker Ltd. (Exeter, UK) and will tell people whether they have immunity against coronavirus and whether that immunity comes from developing antibodies after infection or the vaccine.

The Triple Antibody Test measures three types of antibodies: IgM – the first-responding antibody raised early in the infection; IgG – the long-lasting antibody, persisting in the blood for possibly six months; and IgA – the antibody released on surfaces of the nose and lungs as the first line of defense. These antibodies attack three different parts of the coronavirus: Nucleocapsid - the protein containing the RNA material inside the virus; Spike Protein – the protein that attaches to the surfaces of our cells when the virus invades; and RBD Protein – the part of the spike protein that docks to our cells leading to neutralizing antibodies.

The Triple Antibody Test tells you whether you have natural antibodies because you have had the infection before and which protect you against infection, or if you have vaccine antibodies to protect you against infection. The results appear in real-time and will be an evolving graph which at the end of the test shows the three antibody levels N, S, and RBD along with CRP. If the test reveals that you have antibodies above pre-pandemic levels, then you have some protection and if the results show that you have antibodies below pre-pandemic levels, then you may not have protection against the virus. The results can be downloaded straight to the Biomark App.

“We started off by building the device for Attomarker, but it quickly became apparent that there were other areas where we could assist to deliver the project such as machine validation testing,” explained Robert Badcock, managing director at Mantracourt. “We undertook pre-compliance testing and discovered the electronics and communication systems in the device could be improved. We designed a new power distribution module, new USB components and a USB hub, as well as replacing several of the specified cables in the unit. Overall, we managed to improve the kit while reducing around 60 per cent of the cost and also reduced noise, which is important from an EMC point of view.”

Related Links:
Mantracourt Electronics Limited
Attomarker Ltd.


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.